Yet another article with Synta the only stock mentioned:
It seems as if mergers and acquisitions in the healthcare sector has become commonplace, with a lot of biotech companies being main targets.
Not a week goes by without multiple discussions about the battle between Valeant Pharmaceuticals (NYSE: VRX) and Allergan(NYSE: AGN). Last week brought news of Merck’s (NYSE: MRK) acquisition of Idenix Pharmaceuticals.
Investors in companies that are acquired tend to reap huge paydays, but unfortunately it is difficult to know which companies might be next.
However, Synta Pharmaceuticals (NASDAQ: SNTA) was recently cited in Forbes as having the potential of being acquired. The company focuses on the discovery, development and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases.
Synta has two drug candidates in clinical trials for treating multiple types of cancer, and various drug candidates in the pre-clinical stage of development.